Paramyxovirus fusion (F) protein: A conformational change on cleavage activation

Virology

Volumn 281, Issue 1, 2001, Pages 138-150

  Dutch, Rebecca Ellis ^a   Hagglund, Ryan N ^a   Nagel, Margaret A ^a   Paterson, Reay G ^a   Lamb, Robert A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PAPAIN; VIRUS FUSION PROTEIN;

ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; HELA CELL; HUMAN; HUMAN CELL; MEMBRANE FUSION; NONHUMAN; PARAMYXOVIRUS; PRIORITY JOURNAL; PROTEIN DEGRADATION; VIRUS CELL INTERACTION; VIRUS ENVELOPE;

EID: 0035264638     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0817     Document Type: Article

References (87)

1. Why is a specific amino acid sequence of F glycoprotein required for the membrane fusion reaction between envelope of HVJ (Sendai virus) and target cell membranes?
2. Individual roles of N-linked oligosaccharide chains in intracellular transport of the paramyxovirus SV5 fusion protein
3. Structural basis for paramyxovirus-mediated membrane fusion
4. Structure of influenza haemagglutinin at the pH of membrane fusion
5. Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41
6. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein
7. Influenza hemagglutinin is spring-loaded by a metastable native conformation
8. A spring-loaded mechanism for the conformational change of influenza hemagglutinin
9. Cell fusion by the envelope glycoproteins of persistent measles viruses which cause lethal human brain disease
10. Core structure of gp41 from the HIV envelope glycoprotein
11. HIV entry and its inhibition
12. Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation
13. 2 subunit ectodomain
14. N- and C-terminal residues combine in the fusion-pH influenza hemagglutinin HA2 subunit to form an N cap that terminates the triple-stranded coiled coil
15. Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein
16. Peptide mapping by limited proteolysis in sodium dodecyl sulfate and analysis by gel electrophoresis
17. Receptor-triggered membrane association of a model retroviral glycoprotein
18. Mutations in the Newcastle disease virus hemagglutinin-neuraminidase protein that interfere with its ability to interact with the homologous F protein in the promotion of fusion
19. Localization of a domain on the paramyxovirus attachment protein required for the promotion of cellular fusion by its homologous fusion protein spike
20. Membrane fusion promoted by increasing surface densities of the paramyxovirus F and HN proteins: Comparison of fusion reactions mediated by simian virus 5 F, human parainfluenza virus type 3 F, and influenza virus HA
21. Paramyxovirus fusion protein: Characterization of the core trimer, a rod-shaped complex with helices in anti-parallel orientation
22. The physical basis for induction of protein-reactive antipeptide antibodies
23. The fusion and hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus 3 are both required for fusion
24. Retrovirus envelope domain at 1.7Å resolution
25. 7 RNA polymerase
26. Capture of an early fusion-active conformation of HIV-1 gp41
27. Virus-cell and cell-cell fusion
28. Activation of a retroviral membrane fusion protein: Soluble receptor-induced liposome binding of the ALSV envelope glycoprotein
29. Trypsin action on the growth of Sendai virus in tissue culture cells. III. Structural differences of Sendai viruses grown in eggs and tissue culture cells
30. Studies on the fusion peptide of a paramyxovirus fusion glycoprotein: Roles of conserved residues in cell fusion
31. Biological activity of paramyxovirus fusion proteins: Factors influencing formation of syncytia
32. Activation of the Sendai virus fusion protein (F) involves a conformational change with exposure of a new hydrophobic region
33. Functional interactions between the fusion protein and hemagglutinin-neuraminidase of human parainfluenza viruses
34. Retrovirus envelope glycoproteins
35. Role of a single amino acid at the amino terminus of the simian virus 5 F2 subunit in syncytium formation
36. HIV-1 inhibition by a peptide
37. Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41
38. A core trimer of the paramyxovirus fusion protein: Parallels to influenza virus hemagglutinin and HIV-1 gp41
39. Host cell proteases controlling virus pathogenicity
40. Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins
41. Changes in conformation and charge paralleling proteolytic activation of Newcastle disease virus glycoproteins
42. Paramyxovirus fusion: A hypothesis for changes
43. The synthesis of Sendai virus polypeptides in infected cells. III. Phosphorylation of polypeptides
44. Evidence for a ninth influenza viral polypeptide
45. The paramyxovirus fusion protein forms an extremely stable core trimer: Structural parallels to influenza virus haemagglutinin and HIV-1 gp41
46. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion
47. A trimeric structural domain of the HIV-1 transmembrane glycoprotein
48. Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: Conserved helical interactions underlie the broad inhibitory activity of gp41 peptides
49. Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-Å resolution
50. Dissociation of gp120 from HIV-1 virions induced by soluble CD4
51. Complementation between avirulent Newcastle disease virus and a fusion protein gene expressed from a retrovirus vector: Requirements for membrane fusion
52. Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41
53. Efficient selection for high-expression transfectants by a novel eukaryotic vector
54. Analysis and gene assignment of mRNAs of a paramyxovirus, simian virus 5
55. Fusion protein of the paramyxovirus simian virus 5: Nucleotide sequence of mRNA predicts a highly hydrophobic glycoprotein
56. Expression at the cell surface of biologically active fusion and hemagglutinin-neuraminidase proteins of the paramyxovirus simian virus 5 from cloned cDNA
57. Ability of the hydrophobic fusion-related external domain of a paramyxovirus F protein to act as a membrane anchor
58. The molecular biology of influenza viruses and paramyxoviruses
59. Fusion protein of the paramyxovirus SV5: Destabilizing and stabilizing mutants of fusion activation
60. Analysis of the relationship between cleavability of a paramyxovirus fusion protein and length of the connecting peptide
61. Isolation and characterization of monoclonal antibodies to simian virus 5 and their use in revealing antigenic differences between human, canine and simian isolates
62. A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus-cell fusion: An emerging similarity with functional domains of other viruses
63. A new cationic liposome reagent mediating nearly quantitative transfection of animal cells
64. Electron microscopy of the low pH structure of influenza virus haemagglutinin
65. Studies with cross-linking reagents on the oligomeric form of the paramyxovirus fusion protein
66. Identification of biological activities of paramyxovirus glycoproteins. Activation of cell fusion, hemolysis, and infectivity of proteolytic cleavage of an inactive precursor protein of Sendai virus
67. Mutations in the fusion peptide and heptad repeat regions of the Newcastle disease virus fusion protein block fusion
68. Interactions between HIV-1 gp41 core and detergents and their implications for membrane fusion
69. Coiled coils in both intracellular vesicle and viral membrane fusion
70. Detection of an interaction between the HN and F proteins in Newcastle disease virus-infected cells
71. Atomic structure of a thermostable subdomain of HIV-1 gp41
72. Expression of mumps virus glycoproteins in mammalian cells from cloned cDNAs: Both F and HN proteins are required for cell fusion
73. Alternative mechanisms of interaction between homotypic and heterotypic parainfluenza virus HN and F proteins
74. Biological characterization with particular reference to the conformational change of envelope glycoproteins associated with proteolytic cleavage
75. Mutants of the paramyxovirus SV5 fusion protein: Regulated and extensive syncytium formation
76. Proteolytic cleavage of the fusion protein but not membrane fusion is required for measles virus-induced immunosuppression in vitro
77. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain
78. Atomic structure of the ectodomain from HIV-1 gp41
79. Temperature dependence of fusion by Sendai virus
80. Anti-peptide antibodies detect steps in a protein conformational change: Low-pH activation of the influenza virus hemagglutinin
81. A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition
82. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection
83. Measles virus: Both the haemagglutinin and fusion glycoproteins are required for fusion
84. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution
85. Peptides corresponding to the heptad repeat sequence of human parainfluenza virus fusion protein are potent inhibitors of virus infection
86. Association of the parainfluenza virus fusion and hemagglutinin-neuraminidase glycoproteins on cell surfaces
87. Analysis of a peptide inhibitor of paramyxovirus (NDV) fusion using biological assays, NMR, and molecular modeling